TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06036797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: For those in Group 1 : they will be administered with 15 ug/ml hydromorphone, For those in Group 2 : they will be administered with 17.5 ug/ml hydromorphone, For those in Group 3 : they will be administered with 20 ug/ml hydromorphone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: For those in Group 1 : they will be administered with 15 ug/ml hydromorphone, For those in Group 2 : they will be administered with 17.5 ug/ml hydromorphone, For those in Group 3 : they will be administered with 20 ug/ml hydromorphone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: For those in Group 1 : they will be administered with 15 ug/ml hydromorphone, For those in Group 2 : they will be administered with 17.5 ug/ml hydromorphone, For those in Group 3 : they will be administered with 20 ug/ml hydromorphone
Study: NCT05934812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: 24IU oxytocin liquid delivered with a pump-actuated nasal spray device, administered twice-daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo liquid nasal spray administered twice-daily
Study: NCT04851483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2328065
Description: Solid Form, Oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2328065
Description: Solid Form, Oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2328065
Description: Solid Form, Oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2328065
Description: Solid Form, Oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of BAY2328065.
Study: NCT06577883

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest X-ray Tomosynthesis
Description: An imaging device that uses X-rays projected from multiple angles to reconstruct a three-dimensional images of the chest
Study: NCT06576388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXG001-307 injection
Description: Research process includes filter (subjects signed informed consent for screening period before the pretreatment to the hormone, the longest 28 days), treatment period (the subjects accept including single hormone pretreatment, the study drug infusion) hospitalization and observation and follow-up treatment period (subjects to the participants to 18 months, lost to follow-up, active exit research subjects, or death). Subjects qualified in the screening period entered the treatment period and received EXG001-307, and entered the follow-up period after hospitalization. At the end of the study visit (subject at 18 months of age), eligible subjects will be asked to transfer to the long-term follow-up study.
Study: NCT05534022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test myopia control lenses (BSL)
Description: Myopia control spectacle lenses (test lenses) will be given to subjects throughout the 24 months trial.
Study: NCT06099301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief advice of a list of mobile apps
Description: The mobile apps in the list should: (1) focus primarily on anxiety/depression/stress, (2) be available for free download; (3) be available in English or Chinese; and (4) have a user star rating in the app store.
Study: NCT06412653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Acetate Dihydrate
Description: In this single arm trial, all participants will be receive the trial drug zinc acetate dihydrate orally. The Investigational medicinal product (IMP) will be given one hour after meal in a dosage which is recommended in Wilson Disease and has been given in this condition without observing severe adverse effects. If oral administration is not possible due to the disability level of the patient, the IMP can be mortared and suspended and can then be given as suspension orally or via the Percutaneous endoscopic gastrostomy. The total treatment duration in each patient is 6 months with stable dosage over the duration of the trial. If the therapy shows effects, the parents and participants may continue medication after the end of the trial. If not, they will stop the medication after the last visit at the trial site.
Study: NCT05298150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic cycling
Description: The dynamic cycling involves smart bike that changes according to participants' performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Forced cycling
Description: The same smart bike as used for dynamic cycling, but its adaptive capacity will be disabled. In this case, the bike will behave as standard exercise stationary bike. It will not change its performance according to participants' response.
Study: NCT06577623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MINDful TIME
Description: Group-based psychoeducational mindfulness-based intervention.
Study: NCT04855032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reactive Perturbations
Description: A novel device will be used to apply controlled mediolateral perturbations to participants' trunk as they walk on a treadmill, requiring reactive responses to avoid a loss of balance. All perturbations will have a duration of 200 ms, and will be applied immediately after onset of the swing phase with either the paretic or non-paretic leg. If in a given training session, a participant does not experience any losses of balance, the perturbation magnitude will be increased in the next training session. Perturbations will begin at 3% body weight (BW), and will progress in increments of 3% BW up to a maximum of 15% BW. The structure of the Reactive perturbation session will be identical to that used for Proactive perturbation training sessions, including overground trials, treadmill trials without perturbations, and Perturbed and Catch trials in which Perturbations are delivered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive Perturbations
Description: A novel device will be used to perturb the relationship between pelvis motion and step width by applying mediolateral forces to participants' legs. Participants will first perform a 3-minute overground walking trial at their self-selected speed, in which they do not interact with the perturbation device. Participants will then perform a 3-minute treadmill walking trial at their self-selected speed, in which they again do not interact with the perturbation device. Participants will then perform a series of alternating 3-minute Perturbed and Catch trials, all at their self-selected speed. For the Perturbed trials, perturbations will be delivered in each step throughout the trial. For the Catch trials, perturbations will cease for the final minute of walking. A total of 5 Perturbed and 5 Catch trials will be performed. Finally, participants will perform a 3-minute overground walking trial at their self-selected speed, in which they do not interact with the perturbation device.
Study: NCT05864781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jigsaw Technique
Description: Jigsaw technique is one of the cooperative learning methods. A topic planned to be learned in the lesson is divided into sections and these sections are distributed to the students in the main group. Students who are responsible for the same sections in the groups combine to form expert groups and specialize by working on the subject. They then return to their main group to share their knowledge and make a presentation on the topic.
Study: NCT06329492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP)
Description: Your blood will be processed into Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) A2MRP in the procedure room with you while you wait. This will take approximately 30 minutes. When this is complete, an ultrasound will be done of your knee to determine the best location for injection into the knee joint. You will undergo an ultrasound guided injection, and the needle guided into the knee joint, and the Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) A2MRP will be injected into the joint space. If there is excessive fluid in your knee, this may be drained before the injection is performed. The needle will be removed, and a band aid will be placed over the injection site.
Study: NCT06100419

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: serratus posterior superior intercostal plane block
Description: With this newly introduced procedure added to the literature, patients undergoing breast surgeries are expected to experience reduced pain.
Study: NCT06580613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New model of Hypertension Management
Description: Hypertension management based on cardiovascular risk assessment. For details see description of study arm intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Hypertension Management as usual
Study: NCT06239870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy
Description: Each enrolled patient was given 2 cycles of induction chemotherapy combined with immunization, followed by immunization combined with chemoradiotherapy, and finally 2 cycles of consolidation chemotherapy combined immunization
Study: NCT06491472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab
Description: 20mg/kg,IV,d1,Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2, IV, d1/8, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125mg/m2, IV, d1/8, Q3W

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 5Gy \*5 F
Study: NCT05795101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).
Study: NCT05989100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Favourate taste stimulation
Description: The taste stimulaiton for swallowing is completed with long swab. Taste solution will be prepared with sugar, salt, citric acid, or paprika mixed with water. And the swab will be immersed in the solution and freezed in -18℃ circumstances. Bilateral buccal mucosa，palate and tounge will be brushed. Four swabs will be used in a training session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sour taste stimulation
Description: Using sour swab to brush oral cavity and tounge.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Thermal stimulation group
Description: Only ice-water swab to brush oral cavity and tounge.
Study: NCT05872568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Description: The recommended dose range is 360 to 720mg,bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Description: The recommended dose range is 360 to 720mg,bid
Study: NCT05753150

Intervention type: DRUG
Intervention: Tafenoquine
Description: Tafenoquine 300 mg (2x150 mg tablets)

Intervention type: DRUG
Intervention: Primaquine
Description: Daily primaquine adjusted by weight (0.25 mg/kg/day for 14 days)

Intervention type: DRUG
Intervention: Primaquine
Description: Weekly primaquine adjusted by weight (0.75mg/kg/week for 8 weeks)
Study: NCT05011994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintenance intervention
Description: The intervention consists of action planning, text messages, and coordinator support.~At onset, each participant creates an action plan for physical activity with the help of a health professional:~* What types of physical activities?~* When and how often?~* Where and with who?~  2 auto-generated text messages are sent weekly for a duration of 12 weeks. The first prompts physical activity. The second asks if plans were reached. If yes, an automatic reply with positive reinforcement is generated. If no, an automatic reply asks if the participant wants to be contacted.~Participants are contacted by a coordinator either by answering text messages or if not answering the texts for a period of 2 weeks or more. Coordinator functions:~* Call participants replying to texts that they wish to be contacted~* Help participants establish contact to local activities involving physical activity~* Follow-up on and adjustment of action plan~* Offer guidance in physical activity
Study: NCT05435781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for hydrocortisone
Description: Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
Study: NCT05080777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Savvy
Description: A low-risk, psychoeducational, group-based intervention, is grounded in social learning and stress process theory and its main goal is to produce improved caregiver mastery over the symptom management skills commonly encountered when supervising and caring at home for an older adult living with ADRD. Over the 7-week program, there are synchronous and asynchronous activities each week. The synchronous portion includes weekly scheduled videoconferences (60-80 min) that serve as an online classroom in which facilitators lead lectures and discussions. Daily, caregivers access online 6- to 15-min prerecorded videos, each focused on one main learning objective. Caregivers can watch the lessons whenever and as often as they wish.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiving During Crisis (Educational Program)
Description: The attention control group will receive the self-guided Caregiving During Crisis program. Caregiving During Crisis is a fully online, asynchronous, professionally designed continuing education course aimed at developing the competency of informal caregivers of community-dwelling persons living with dementia to ensure the safety of that person and themselves during this time of the COVID-19 pandemic. The course, readily accessible by home computer or smartphone, describes methods of home infection control and prevention to create a Safe Home space, strategies for safely leaving and re-entering the home (e.g., to shop), additional strategies for safely allowing service personnel (e.g., home health aides or electricians) and select family members to enter the Safe Home space, and risk management strategies to frame decisions when/if COVID restrictions are relaxed or revoked.
Study: NCT06221579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention, interviews with MCI patients as part of the development phase
Description: No intervention, interviews with MCI patients as part of the development phase
Study: NCT06059105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate Implant Surgery
Description: Inverted Co-Axis 12º Southern Implants

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Implant Surgery
Description: Internal Conical (Deep Tapered Conical) South Implants
Study: NCT06334523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ventilation
Description: the premature infant will be ventillad by respirator and medical device S-lem for reduce the Continuous Tracheal Gas Insufflation (CTGI). The CTGI is a ventilation option conventional to reduce or even cancel space anatomical death due to respiratory prostheseses.
Study: NCT05089838

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-TCR-T cells
Description: Patients who developed refractory CMV infection after allo-HSCT will be enrolled, and donor derived CMV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.3-1×10E7CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).
Study: NCT06294496

Intervention type: PROCEDURE
Intervention: CEA/CAS
Description: carotid endarterectomy (CEA) and carotid artery stenting (CAS)

Intervention type: PROCEDURE
Intervention: CEA/CAS
Description: carotid endarterectomy (CEA) and carotid artery stenting (CAS)
Study: NCT04848428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online mindfulness-based cognitive therapy
Description: The first session will first focus on providing feedback regarding post-surgical pain. The second session will focus on teaching mindfulness strategies. The third session will focus on practicing one of the two strategies. Of note, sessions 2 and 3 will start with cognitive restructuring strategies for the moderate-high risk profile patients. The 4th session consists in a booster providing feedback and reminders about cognitive reactions to pain and mindfulness meditation. The participants will be asked to practice meditation 5 days a week, for a total of 4 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online standardized education
Description: One 15-minute educational session on postoperative pain, the relationship between pain, thoughts and emotions and brief overview of strategies.
Study: NCT04621110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal dexmedetomidine
Description: Dexmedetomidine (precedex®) will be administered by intranasal route in 1ug/kg each dose, repeating at most 3 times to see if it can give enough sedation to painful procedure. To assess the level of sedation the study will use Ramsay sedation scale.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal fentanyl
Description: Fentanyl will be administered by intranasal route in 1,5ug/kg each dose, repeating at most 3 times to see if it can give enough pain relief for painful procedure. To assess pain control the study will use Face, Legs, Activity, Cry, Consolability scale ( FLACC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous ketamine (ketalar®)
Description: Ketamine (ketalar®) will be administrated by intravenous route in 1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous midazolam
Description: Midazolam will be administrated by intravenous route in 0,1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.
Study: NCT04839965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ampion
Description: Ampion administered via intravenous infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo administered via intravenous infusion
Study: NCT06036797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: For those in Group 4 : they will be administered with 0.4 ug/ml sufentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
Study: NCT06084455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 30 minutes of aerobic exercise on a stationary bike
Study: NCT05558722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib (12 mg qd, d1-14; 21 days per cycle; total 5 cycles) Combined TAC×6 cycles: albumin-bound paclitaxel (200mg/m2, 1d Q3W) + pirarubicin （50mg/m2, 1d Q3W) + cyclophosphamide (500mg/m2, 1d Q3W);
Study: NCT04896268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: Rafaelo's technique consists of delivering a low-temperature 4 MHz radiofrequency wave current into the haemorrhoidal vascular tissue using a large single-use needle with microfibre electrodes at the end.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arterial ligation then recto-anal repair with Doppler
Description: The aim of arterial ligation is to de-arterialise the haemorrhoids by reducing the arterial flow of the haemorrhoidal plexuses while avoiding obstructing the venous return.
Study: NCT05772221

Intervention type: OTHER
Group type: OTHER
Intervention: Screening
Description: Screening assessments to measure social determinants of health in relation to cardiovascular disease.
Study: NCT06122636

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The probiotic to be used in the intervention corresponds to PRODEFEN Plus manufactured by ITALFARMACO S.A. laboratory
Description: Each patient should take 1 sachet per day, dissolve it in a glass of water, hold in the mouth for 2-3 minutes and then swallow, for a period of 30 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered in an envelope with the same packaging, size, shape and color of contents as the intervention of interest, except that the placebo will not contain the active ingredient of the intervention.
Study: NCT06089343

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CT angiography
Description: Comprehensive hemodynamic and plaque features derived from CTA and verified by OCT of all culprit and non-culprit lesions to predict ACS.

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CT angiography
Description: Comprehensive hemodynamic and plaque features derived from CTA and verified by OCT of all culprit and non-culprit lesions to predict ACS.
Study: NCT05068414

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood panel
Description: * Thrombin generation test~* Residual plasma concentration of dabigatran, rivaroxaban and/or apixaban (direct oral anticoagulants)~* International Normalized Ratio (if anti-vitamin K therapy is prescribed)~* Platelet aggregation test